Hypocalcaemia after intravenous bisphosphonate

BMJ

Volumn 328, Issue 7453, 2004, Pages 1439-1440

  Peter, Rajesh ^a   Mishra, Vinita ^a   Fraser, William D ^a  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; IMIDAZOLE DERIVATIVE; ZOLEDRONIC ACID; PAMIDRONIC ACID;

CHEMICALLY INDUCED DISORDER; HUMAN; HYPOCALCEMIA; INTRAVENOUS DRUG ADMINISTRATION; NOTE; DRUG LABELING; HYPERCALCEMIA; CALCIUM BLOOD LEVEL; CASE REPORT; DRUG DOSE REGIMEN; DRUG INFORMATION; HYPOMAGNESEMIA; LETTER; MEDICAL DOCUMENTATION; PRIORITY JOURNAL; VITAMIN SUPPLEMENTATION;

DIPHOSPHONATES; HUMANS; HYPOCALCEMIA; INFUSIONS, INTRAVENOUS; DRUG LABELING; HYPERCALCEMIA; IMIDAZOLES;

EID: 2942705947     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.328.7453.1439-c     Document Type: Letter

References (5)

1. Major P, Lortholary A, Hon J, Abdi E, Mills G, Menssen HD, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001; 19: 558–67.
2. Ross JR, Saunders Y, Edmonds PM, Patel S, Wonderling D, Normand C, et al. A systematic review of the role of bisphosphonates in metastatic disease. Health Technol Assess 2004; 8: 1–176.
3. British Association of Surgical Oncology Guidelines. The management of metastatic bone disease in the United Kingdom. Eur J Surg Oncol 1999; 25: 3–23.
4. Brown JE, Neville-Webbe H, Coleman RE. The role of bisphosphonates in breast and prostate cancers. Endocr Relat Cancer 2004; 11: 207–24.
5. Saarto T, Blomqvist C, Virkkunen P, Elomaa I. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol 2001; 19: 10–17.